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Abstract
In the absence of intervention, early-onset congenital disorders lead to pregnancy loss, early death, or disability. Currently, lack of
epidemiological data frommany settings limits the understanding of the burden of these conditions, thus impeding health planning,
policy-making, and commensurate resource allocation. The Modell Global Database of Congenital Disorders (MGDb) seeks to
meet this need by combining general biological principles with observational and demographic data, to generate estimates of the
burden of congenital disorders. A range of interventions along the life course can modify adverse outcomes associated with
congenital disorders. Hence, access to and quality of services available for the prevention and care of congenital disorders affects
both their birth prevalence and the outcomes for affected individuals. Information on this is therefore important to enable burden
estimates for settings with limited observational data, but is lacking frommany settings. This paper, the third in this special issue on
methods used in the MGDb for estimating the global burden of congenital disorders, describes key interventions that impact on
outcomes of congenital disorders and methods used to estimate their coverage where empirical data are not available.
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Introduction
In the absence of intervention, early-onset congenital disor-
ders lead to pregnancy loss, early death, or disability. A range
of interventions along the life course can modify these out-
comes. Preventive interventions before pregnancy include
anti-D for rhesus-negative mothers following previous preg-
nancies to prevent iso-immunisation (Zipursky and Bhutani
2015), vitamin supplementation, e.g. folic acid food fortifica-
tion or supplementation and multi-vitamin supplementation
(De-Regil et al. 2015; Haider and Bhutta 2015), and pre-
pregnancy counselling based on risk identification, e.g. of
genetic conditions, maternal chronic conditions and infections
(Hussein et al. 2015; Shannon et al. 2014; Verma and Puri
2015). Interventions during pregnancy require prenatal diag-
nosis. If a fetus is affected, options may include treatment
during pregnancy, termination of pregnancy, or planned preg-
nancy, labour and neonatal care. Interventions after birth de-
pend on early case-finding (including physical and biochem-
ical neonatal screening), and further clinical management re-
quiring multi-disciplinary teams with various specialist exper-
tise (e.g. medical geneticists, paediatricians, paediatric sur-
geons, dieticians, physiotherapists, occupational therapists,
cardiologists) and/or primary health and social care. Figure 1
shows the range of possible outcomes for affected conceptions
when interventions are in place.
A range of services and delivery mechanisms are required
for the provision of these interventions, which can include
whole population programmes (e.g. folic acid fortification),
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primary health care (e.g. immunisation for rubella), more
targeted clinical interventions (e.g. surgery for orofacial clefts)
and social support. Furthermore, surgical and non-surgical
treatments for congenital disorders can vary widely in their
resource requirements, which can influence their availability
in different settings, as can the perception of these disorders as
an important health issue. Interventions before or during preg-
nancy impact on affected birth prevalence, whilst interven-
tions after birth impact on mortality and long-term morbidity
and functioning. Hence, the existence of, level of access to,
and quality of interventions and services available for the pre-
vention and care of congenital disorders will affect both their
birth prevalence and the outcomes for affected individuals.
Efforts to estimate the burden of these disorders should there-
fore take these into account (Moorthie et al. 2017c).
TheModell Global Database (MGDb) has been developed
to seek to overcome gaps in observational epidemiological
data for congenital disorders in many settings by generating
estimates for these conditions combining general biological
principles with available observational data (Moorthie et al.
2017c). Baseline birth prevalence (i.e. prevalence of the con-
genital disorder at birth in the absence of any intervention)
provides a basis for making further estimates, as it provides
the envelope into which all outcomes must fit (Moorthie et al.
2017c). Processes for estimating the baseline birth prevalence
of specific congenital disorders within the MGDb are given in
accompanying papers in this supplement (Moorthie et al.
2017a; Moorthie et al. 2017b; Moorthie et al. 2017c), with a
full description available online (Modell et al. 2017). Once
estimates are available for baseline birth prevalence,
country-specific outcomes can be calculated based on data
on the impact of specific interventions and the proportion of
the population with access to these interventions. The out-
comes which can be considered include birth outcomes (ter-
mination of pregnancy, fetal death, live birth); early mortality
(neonatal, infant, under-5 deaths /1000 births); proportion of
survivors at 5 years effectively cured, or living with mild-to-
moderate or severe disability; and mean age at death.
MGDbmodels severe, early-onset congenital disorders that
cause early death and/or life-long disability in the absence of
Fig. 1 Interventions for congenital disorders along the continuum.
Affected conceptions are depicted in this figure, but not quantified in
MGDb. aIncluding maximising the control and appropriate medications
in pregnancy for chronic conditions including HIV, epilepsy and diabetes.
bIncluding delivery in a hospital with neonatal intensive care/surgical
capabilities, planned caesarean section. cIncluding neonatal physical
exam, biochemical screening, e.g. dried blood spot, hearing screening
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care and present before 20 years of age. These include con-
genital malformations such as congenital heart disease,
chromosomal disorders such as Down syndrome, and a
number of inherited disorders. Full details are available
in the previous paper in this series (Moorthie et al.
2017c). All these conditions have relatively constant birth
prevalences in the absence of interventions. MGDb does
not currently include disorders resulting primarily from
exposure to external risk factors such as congenital infec-
tions, toxins or environmental factors. This is because risk
varies more widely with place and time, requiring
country-specific data which is currently not available.
In this article, the third in this special issue on methods for
estimating the global burden of congenital disorders, we de-
scribe the interventions currently included in the MGDb and
the methodology used for estimating coverage of these ser-
vices (Table 1). We also describe the approach taken to esti-
mate their impact. Provisional national and regional estimates
using MGDb methodology are available online at http://
discovery.ucl.ac.uk/1532179/.
Estimating access to services
Information on access to services, including specialist services
such as genetic counselling and paediatric surgery, including
cardiac surgery, is important to estimate the burden of congen-
ital disorders. In MGDb, information on access to individual
elements or packages of services is used where available for a
specific country. However, for many countries, comprehen-
sive data on the coverage of these services are not available.
For these countries, we sought to provide an estimate of access
to a comprehensive package of ‘optimal care’. For the pur-
poses of these estimates, optimal care is defined as the stan-
dard of care available in high-income settings with equitable
access to services. In principle, this could be achieved using a
combination of relevant health index proxies, such as average
life expectancy, or neonatal, infant or under-5 mortality, or the
proportion of the population that is urbanised. However, since
these measures are all highly correlated (online resource:
(Figure i, Table i)) and consistent with previous global peri-
natal estimates, we chose to select a single proxy indicator to
estimate access to optimal care services.
The World Health Organization’s Child Health
Epidemiology Reference Group (CHERG) used neonatal
mortality rates (NMR) to define levels of access to care for
estimates of long-term outcomes following neonatal condi-
tions. This decision was based on their collective expert expe-
rience that a NMR of > 30/1000 indicates very limited access
to health services, but that access increases rapidly as coun-
tries pass through the development window, and a neonatal
mortality < 5/1000 indicates near 100% access (Blencowe
et al. 2013). Infant mortality rate (IMR) is closely correlated
with NMR (coefficient of correlation = 0.93, Online resource
Figure ii). In MGDb, we use IMR, for which country esti-
mates (1950–2015) and projections to 2100 are available
(UN Population Division 2015), in preference over NMR
which is available for a more limited time period, thus
allowing the generation of estimates for historical time pe-
riods, and for future projections under different intervention
scale-up scenarios. In addition, in many countries, sub-
national data are more readily available for infant mortality
Table 1 Included interventions affecting the birth prevalence and outcomes of congenital disorders
Timing of
intervention
Intervention Mechanism of intervention effect Method used to estimate coverage in MGDb
Preconception Anti-D for rhesus-negative mothers Conversion of potential affected
pregnancy to unaffected pregnancy
Modelled estimate of access to ‘optimal care’a
Folic acid food fortification Observational data or for countries with mandatory
fortification and no data modelled based
Wald et al. (Wald 2001)
Identification of genetic risk,
information, genetic counselling
Informed reproductive choice Retrospective risk information coverage: modelled
estimate of access to optimal carea
Prospective risk information coverage: for countries
without data assumed to be zero coverage
Pregnancy Identification of increased risk,
information, genetic counselling.
Prenatal diagnosis
Intra-uterine treatment Not currently included
Option of termination of pregnancy Observational data or for countries where TOP legal
prenatal diagnosis coverage estimated to be equal
to optimal care* and proportion opting for TOP
based on EUROCAT rates (see text for details)
After birth Early diagnosis and care Appropriate, timely neonatal diagnosis
and care
Modelled estimate of access to optimal carea
Ongoing treatment and supportive care Modelled estimate of access to optimal carea
aModelled estimate of access to ‘optimal care’ based on adjusted IMR (see webappendix page3)
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than for other candidate indicators, allowing sub-national es-
timates to be generated.
Table 2 shows the five neonatal mortality groups used by
CHERG, the corresponding infant mortality groups and esti-
mated proportion of the population with access to services
(Blencowe et al. 2013). This method has the advantage of
encapsulating the experience of experts within CHERG, but
its step-wise nature gives rise to undesirable discontinuities,
particularly as, with time, countries move across boundaries
(Online resource Figure iii). We refined this method further by
deriving a curve to represent the estimated relationship be-
tween access to care and IMR, based on the Beta family of
distributions (see Online resource page 4 for details). Figure 2
shows the general relation of infant mortality to estimated
access, calculated using the mortality groups in Table 2 (blue
line) and the continuous curve that was fitted to it (red line).
Adjustments to estimates of access to care based
on infant mortality rates
We undertook adjustments to the IMR as a proxy indicator of
access to care to account for the effects on IMR of parental
consanguinity and HIV infection as detailed below.
Adjustment of IMR for prevalence of parental consanguinity
Early-onset congenital disorders contribute significantly to in-
fant mortality; hence, there is potential circularity in using
IMR to estimate access to care. This is minimal for chromo-
somal disorders and congenital malformations where the base-
line prevalence is similar in most populations (Moorthie et al.
2017a, b). For single gene disorders, which may be consan-
guinity-associated, the baseline prevalence differs substantial-
ly between populations. We therefore adjusted the IMR to
account for the increased contribution of infant deaths from
consanguinity-associated disorders to overall IMR to seek to
improve the estimate of access to care services.
The consanguinity-adjusted IMR is calculated as follows:
Consanguinity adjusted IMR ¼ IMR−cIMR
where cIMR is the consanguinity-associated IMR calculat-
ed from (a) local coefficients of consanguinity (a measure of
gene pairs that are identical in offspring because they are
inherited from recent common ancestor(s)) (Bittles 2001));
(b) mortality from consanguinity-associated disorders in the
absence of care and with optimal care (Bittles and Black 2010;
Bittles and Neel 1994; Bundey and Alam 1993); and (c) esti-
mated access to care as described (see Online resource page
4). This initial adjustment over-estimates consanguinity-asso-
ciated mortality and so over-reduces the infant mortality rate;
hence, further iterations were undertaken until a stable adjust-
ed IMR was achieved (see Online resource page 5). After two
iterations, further iterations made little difference to the adjust-
ed IMR, and therefore, two iterations were undertaken.
This adjustment has a marked effect for countries with a
high prevalence of parental consanguinity that are on the
steepest part of the development curve (i.e. infant mortality
between 10 and 35/1000), many of which are located in the
EasternMediterranean region (Fig. 3). The effect is minimal at
low levels of IMR, where high levels of access to care limit the
number of infant deaths, and at high levels of IMR where the
proportion of all mortality attributable to these disorders will
be relatively low.
Adjustment of IMR for AIDS-related infant mortality
The HIV/AIDS epidemic has had a substantial effect on infant
mortality in a number of countries over the past two decades,
particularly in sub-Saharan Africa (Institute for HealthMetrics
and Evaluation (IHME) 2015; Liu et al. 2017). In these set-
tings, using an unadjusted IMR may underestimate the access
to care, and hence, we undertook a further adjustment to the
IMR by subtracting HIV-related infant mortality (hivIMR).
Although the contribution of HIV/AIDS to infant mortality
in sub-Saharan Africa is substantial, it has a relatively small
Table 2 Estimated proportion of the population with access to services by mortality group
Group no. Mortality level Services for
congenital disorders
Neonatal mortality
range
Corresponding infant
mortality rangea
Estimated % access
to optimal careb
1 Very low Optimal ≤ 5 ≤ 9 100%
2 Low Evolving 6–15 10–24 50%
3 Moderate For some 16–30 25–54 15%
4 High For few 31–45 55–99 5%
5 Very high For none > 45 100 plus 0%
a Five infant mortality groups corresponding to the CHERG neonatal mortality groups were defined using the relationship between IMR and NMR in
1990 (webappendix Fig. 2)
b Data source: Child Health Epidemiology Reference Group (CHERG) described in Blencowe et al. (2013)
J Community Genet
effect on estimated access to services in most countries in the
region because infant mortality is still > 40/1000.
Estimates of access to care adjusted for consanguinity
and HIV/AIDS
The final adjusted IMR is calculated as follows:
Final adjusted IMR ¼ consanguinity adjusted IMR−hivIMR
Final access to care was estimated using the adjusted
IMR and the access to care equation (Online resource
page 4, Table ii). The effects of the adjustments are shown
by WHO region in Table 3. Currently, in MGDb, access
to care is a binary variable. We have assumed that those
who do not have access to optimal care have no access to
any ‘supportive medical services’. This is an over-
simplification which may under-estimate the impact of
interventions in some settings as services are scaled-up.
In particular, in low- and middle-income settings, services
requiring very high level of trained and supportive staff,
for example surgical care for complex congenital heart
disease, are likely to be scaled-up later than services re-
quiring less intensive diagnostic and surgical skills, for
example surgical repair of oro-facial clefts.
Interventions that impact on birth outcomes
This section provides further details on the interventions
that impact on birth outcomes currently included in the
MGDb (Table 1).
Prevention of iso-immunisation of Rh-negative
women
Prevention of rhesus isoimmunisation following miscarriage
or delivery protects the next pregnancy from rhesus
haemolytic disease of the newborn. In high-resource coun-
tries, a pincer movement of improved prevention and im-
proved management has practically eradicated mortality
and morbidity due to Rh incompatibility (Zipursky and
Bhutani 2015). Routine post-partum administration of anti-
D protects most Rh-negative women. The addition of routine
anti-D during pregnancy has reduced maternal immunisation
to almost zero (Clarke and Whitfield 1984; Tovey 1984).
Whilst rhesus negativity is commonest in populations of
European origin, it can occur in any population. Absence
of national policies integrating diagnosis and prevention into
pregnancy care in many low- and middle-income countries
(LMICs) have led to it remaining an important preventable
cause of adverse birth outcomes in these settings.
Previous estimates have sought to quantify the coverage of
anti-D based on sales data of Rhesus immunoglobulin from
registered companies (Bhutani et al. 2013). Whilst this previ-
ously provided a reasonable estimate of coverage, recent pro-
liferation in the number of manufacturers and the increasing use
of monoclonal substitutes nowmake this approach challenging.
In MGDb, the coverage of anti-D is assumed as a minimum to
be equal to the estimated access to optimal care. As this may
underestimate access in countries where detection of Rh nega-
tivity and provision of anti-D is considered standard obstetric
practice and coverage will depend on reach of maternity ser-
vices, maximum coverage in these countries is assumed to be
equal to the coverage of four antenatal care visits (see Modell
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et al. (2017) for further details). Country-specific data on the
utilisation of anti-D are needed to improve estimates.
Folic acid
Maternal folate intake influences the risk of neural tube de-
fects (NTDs), including anencephaly, spina bifida and
encephalocoele. Although adequate intake of folic acid does
not prevent 100% of cases, due to other environmental and
genetic factors that influence the risk of NTD, studies have
shown it to be an effective preventative strategy (Blencowe
et al. 2010). There is strong evidence to support a positive
effect of mandatory folic acid fortification on NTDs (Atta
et al. 2016; Williams et al. 2015; Zaganjor et al. 2016).
The effect of folic acid food fortification is dependent on
dose and affected birth prevalence. Small doses lead to a
marked reduction when birth prevalence is high, and earlier
studies showed that fortification with around 2 ppm will re-
duce total neural tube defect birth prevalence to < 1/1000
births, regardless of the pre-fortification birth prevalence
(Taruscio et al. 2003; Wald 2001; Zimmerman 2010) (Fig. 4,
Online resource Table iii). Large-scale surveillance data with
prenatal ascertainment from the USA have reported a reduc-
tion of birth prevalence of spina bifida and anencephaly to
around 0.7/1000 (Williams et al. 2015). Accounting for
encephalocoeles, assuming their prevalence to be 11.5% of
that of neural tube defects, we have assumed that this baseline
rate for ‘non-folic-acid-preventable’ neural tube defects to be
0.77/1000 and that this applies to all populations (Arth et al.
2016; Williams et al. 2015) (Online resource Table iv).
In MGDb, observed pre- and post-fortification birth prev-
alences of NTDs have been used when available. For coun-
tries without observational data, we have estimated folate-
preventable neural tube defects as the total observed (or
Fig. 3 Relationship between infant mortality and estimated access to care for 40 lowmortality countries. Lowmortality is defined as an IMR less than 50
per 1000 live births
Table 3 Effects of adjustment for consanguinity and HIV/AIDS on access to care estimates by World Health Organization (WHO) region
WHO region
or sub-region
Births, 1000 s IMR (WPP) Contribution of % with access to optimal care, based on
Consanguinity-associated
IMR
HIV-related IMR Unadjusted IMR Final adjusted IMR
(% increase in access)
AFR total 34,230 62.6 1.49 1.11 7.7 8.4 (5.5)
AMR total 15,319 15.8 0.15 0.01 63 63 (0.7)
EMR total 17,323 45.6 4.35 0.05 25 30 (21.5)
EUR total 11,296 10.7 0.52 0.01 87 88 (1.8)
SEAR total 37,304 37.3 1.16 0.03 18 19 (4.0)
WPR total 24,368 13.3 0.13 0.01 85 86 (0.9)
World 139,840 35.8 1.30 0.29 39 40
AFR African region, AMR American region, EMR Eastern Mediterranean Region, EUR European region, SEAR Southeast Asian region,WPRWestern
Pacific region
J Community Genet
estimated) baseline birth prevalence (in the absence of folic
fortification) minus the non-folic-acid-preventable neural tube
defects (0.77/1000). Evidence suggests that folic acid supple-
mentation or voluntary fortification has little impact, and we
have therefore assumed no effect of these interventions (De-
Regil et al. 2010; Khoshnood et al. 2015). For countries with
mandatory fortification but without observational data, we
have estimated the number of NTDs prevented from the for-
tification level using the data in Fig. 4, and the estimated
proportion of the population reached by fortification. It is as-
sumed that folic acid food fortification has the same effect on
all neural tube defects, although data from the USA suggest a
more marked effect on spina bifida than on anencephaly
(Alasfoor et al. 2010; Besser et al. 2007; NBDPN 2009)
(Online resource Table iv).
Some studies also support a possible effect of folic acid on
other malformation groups including orofacial clefts and con-
genital heart disease (Bedard et al. 2013; Botto et al. 2006;
Feng et al. 2015; Johnson and Little 2008; Leirgul et al. 2015;
Li et al. 2012; Liu et al. 2016; Wehby and Murray 2010).
Whilst the evidence is not yet conclusive, it is biologically
plausible, and a small effect of folate fortification on oro-
facial clefts and congenital heart disease is therefore included
currently in MGDb (Modell et al. 2017).
There is interest in the potential of vitamin B12 to reduce
vitamin-sensitive congenital malformations, and vitamin B12
is included in the food fortification policies in some countries.
However, to date, the evidence to quantify the effectiveness
for this approach is lacking, and we have not estimated its
effect within MGDb.
Prenatal diagnosis and termination of pregnancy
The common objective of prenatal diagnostic services is to
provide pregnant women with definitive fetal diagnoses.
Definitive fetal diagnoses can facilitate informed discussions
with parents around management options. Where termination
of pregnancy (TOP) for fetal impairment is legal, these dis-
cussions include the option of termination where culturally
acceptable and the implications of continuing with an affected
pregnancy. However, in all settings, prenatal diagnosis allows
women with continuing pregnancies to receive supportive
care and tailored management throughout pregnancy, child-
birth and into childhood. Diagnosis may be through fetal
anomaly scanning or laboratory techniques to identify bio-
markers that indicate an affected fetus. There are no readily
accessible observational data on the spread of methods for,
and utilisation of, prenatal diagnosis in most countries.
Prenatal screening policies, when present, vary across coun-
tries from actively offering screening and prenatal diagnosis to
every pregnant woman, to more restricted policies, e.g. cov-
ering only older women or those with a recognised increased
risk. The type of screening policy impacts on pregnancy out-
come, e.g. in European countries where TOP is legal, a re-
stricted screening policy is associated with lower rates of TOP
for Down syndrome and spina bifida compared to countries
with universal screening (Online resource page 10) (Boyd
et al. 2008).
TOP for congenital disorders is not only affected by screen-
ing policy and availability of prenatal diagnosis but also by the
legal status, national policy and clinical practice of TOP for
fetal impairment in the country (UN Population Division
2013). The assumptions currently used are shown in Table 4,
with further details in Online Resource Table v-vii. High-
quality observational data on TOP are available for 25 coun-
tries in Europe, North America and Australasia, and these are
used as reported (Group A) (European Surveillance of
Congenital Anomalies (EUROCAT) n.d.; International
Clearing House for Birth Defects n.d.). For countries where
there are no observational data, but termination for fetal im-
pairment is legal (Group B) (United Nations 2014), it is as-
sumed that (a) prenatal diagnosis is incorporated into routine
pregnancy care as it develops; (b) for those with access to
prenatal diagnosis, average EUROCAT rates for termination
Fig. 4 Effect of different doses of
folic acid flour fortification in
relation to initial birth prevalence
of neural tube defects. Data
source: Wald (2001). x parts/
million = x μg folic acid per 100 g
flour
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of pregnancy apply for all congenital anomalies except Down
syndrome and spina bifida; and (c) unless there is an explicit
universal screening policy, termination rates for Down syn-
drome and spina bifida are 50% of average EUROCAT rates.
For countries with no high-quality observational data
where TOP for fetal impairment is illegal or where its status
is unclear, we undertook consultations with experts and a
Web-based review for evidence to support the practice of
TOP. Evidence to suggest the widespread practice of offering
the option of TOP for fetal impairment was found for seven
countries (group C) Table 4, Online resource Table vi). For all
other countries, we assume that no pregnancies are terminated
for fetal impairment (group D) (UN Population Division
2013). A limitation of this approach is that in many countries,
there are gaps between legal status, official policy and clinical
practice, and this approach by underestimating the number of
TOPs will effectively overestimate the number of affected
births and congenital associated mortality and disability
(Online resource page 11).
Genetic counselling and associated medical genetic
services
Any genetic diagnosis involves the family as well as the pre-
senting individual. Relatives need information on the mode of
inheritance and possible health and reproductive risks for
themselves, access to definitive diagnosis when this is avail-
able and supportive genetic counselling.
Globally, family studies can often prospectively identify
relatives at risk for dominant and X-linked disorders.
However, for recessive disorders, the great majority of at-
risk couples are identified retrospectively (i.e. through the di-
agnosis of the first affected child).
For some recessive conditions risk can also be identified
prospectively (i.e. before the birth of any affected child) by
systematic carrier screening, or rarely through prospective
family studies, especially in populations with high rates of
consanguineous marriage (Ahmed et al. 2002). Systematic
carrier testing is not yet feasible for most single gene disorders
and is practised on a large scale only for haemoglobin disor-
ders, although technological advances, such as genome scan-
ning, may change the feasibility of widespread prospective
identification of a greater number of disorders in the future
(Bell et al. 2011; Gelb 2013; Himes et al. 2017; Teeuw et al.
2014; Yang et al. 2013). Evidence from beta-thalassaemia pre-
marital screening shows that non-directive risk information
has little effect on final choice of marriage partner
(Alhamdan et al. 2007; Angastiniotis and Hadjiminas 1981;
Zeinalian et al. 2013), even when prenatal diagnosis is not
available (Alhamdan et al. 2007; Stamatoyannopoulos
1974). At the population level, a range of factors determines
the effect of risk information on affected birth rate. These
include whether risk is detected retrospectively orTa
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prospectively, the reproductive aims of at-risk couples, their
access to services and the population norm for final family
size.
Potential effect of retrospective risk information
for recessive disorders
When affected children are not diagnosed, parents cannot be
informed of their risk and in MGDb, they are assumed to
reproduce according to the population norm, with 100% of
expected birth prevalence for the condition (Fig. 5). The
Hardy-Weinberg equation is used to estimate baseline affected
birth prevalence (Aguzzi et al. 1978). The actual birth preva-
lence may be higher due to replacement of affected children
who have died.
Following the diagnosis of an affected child, parents in-
formed of the recurrence risk may take steps to avoid another
affected pregnancy. When preimplantation or early pregnancy
diagnosis services are available, at-risk couples can complete
their desired family size while avoiding the birth of a second
affected child. When prenatal diagnosis is not available, if all
retrospectively detected at-risk couples stopped reproducing
in order to avoid recurrence, the birth prevalence would sim-
ilarly fall. However, in practice for countries where observa-
tional data are available such as the UK and Iran, the majority
of at-risk couples with fewer than two healthy children under-
take further pregnancies in the hope of obtaining unaffected
children (Petrou et al. 2000; Safari Moradabadi et al. 2015).
Data on reproductive practices from other higher-fertility set-
tings are not available; however, the maximum theoretical
possible effect of retrospective risk information at the popula-
tion level is a 50% fall in affected birth prevalence for settings
with an average final family size is six or more (Fig. 5).
However, as average family sizes are decreasing rapidly
in many settings, including LMICs, the current global
average is 2.5 children. Hence, the maximum possible
effect of retrospective risk information at a global level
would be a 15% fall in affected births, although the effect
would be greater for countries that still have high fertility
(UN Population Division 2015).
Potential effect of prospective risk information
The identification of at-risk couples before they have any af-
fected child, for example through premarital or preconception
screening, permits a wider range of options (Petrou et al.
2000). In practice, many such couples limit their family to
two healthy children (Boyd et al. 2008). Figure 5 shows the
theoretical maximum possible effect of prenatal diagnosis on
the calculated fall in affected birth prevalence when carrier
Fig. 5 Estimated effect of genetic counselling for severe recessive disorders, in relation to family size. TFR = total fertility rate; Retro risk info =
retrospective risk information; Prospo risk info = prospective risk information; PND = prenatal diagnosis; Unaff’d = unaffected
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couples are detected prospectively, and stop reproducing
when they have two healthy children. Where prenatal diagno-
sis is not available, the affected birth prevalence would fall by
around 50% when the norm for average family size is six or
more, but there is no effect when it is less than 3. When
prenatal diagnosis is available, the effect depends on the pro-
portion of at-risk couples who access these services, and the
perceived severity of the disorder. Evidence from β-
thalassaemia screening programs shows a maximum reduc-
tion in affected births of over 95% (Fig. 5) (Angastiniotis
et al. 1986; Mitchell et al. 1996; Zeinalian et al. 2013); whilst
evidence from sickle cell disorder screening in the UK, which
is perceived as a less severe disorder, found that only 15% of
at-risk couples opt for prenatal diagnosis and TOP.
In conclusion, a package of prospective detection of genetic
reproductive risks, coupled with access to comprehensive fam-
ily planning and prenatal diagnosis services, is currently the
most effective intervention to substantially reduce the birth
prevalence of inherited genetic disorders. Ideally, all women
and their families should have access to this full package and
sufficient information and support to make their reproductive
choices, which will vary depending on many factors including
the individual’s culture and beliefs. However, access to this full
package of patient services remains low, even in many high-
income settings, and even when resources are available is fre-
quently dependent on political choice regarding population
screening. A global network of collaborators provided informa-
tion on the coverage of prospective risk screening used in
MGDb (Modell and Darlison 2008). In practice, retrospective
risk identification is more commonly available. In MGDb, we
assume that the proportion of affected children diagnosed and
whose parents received genetic counselling is equal to the pro-
portion with access to services, calculated as above.
Included interventions that impact
on mortality and disability
The majority of individuals affected by congenital disorders
require specialist management, frequently with ongoing care
Table 5 Timeline of interventions that impact on mortality and disability outcomes for congenital disorders
Intervenon 1940s 1950s 1960s 1970s 1980s 1990s 2000s 2010 -
Pre- pregnancy intervenons
Rhesus disease Exchange 
transfusion
an-D, Rh-ve mothers
For neural tube defects Vitamin supplements FA ﬂour forﬁcaon
Single gene disorders Counselling on recurrence risk
Tay-Sachs & Hb disorder Pre-concepon carrier screen
Chromosomal disorders Amnio, older 
mothers
Serum markers, 1st 
trimester PND
US markers, universal 
screen
1st trimester screen, 
pre-preg diagnosis
Neural tube defects Amnio & AFP Maternal serum AFP, 
ultrasound
Roune fetal anomaly 
scan
1st trimester US
Congenital heart disease 4-chamber scan
Other congenital malformaons Roune fetal 
anomaly scan
Hb disorders Carrier screen, 
2nd trim PND
CVS & DNA: 
1st trim PND
Other single gene
Rhesus disease
Chromosomal disorders Mandatory care Repair of CHD
NTD (spina biﬁda) Selecve closure roune closure
Oro-facial cles Surgical repair
Pyloric stenosis Surgical repair
Congen heart disease Repair PDA Repair "mild" defs Cardiac echo Repair "complex" defects (open heart) Non-invasive repair
Limb Orthopaedics
Other congenital malformaons NN exam: surgical repair
Congen hypothyroidism NN screen, Rx
Hb: thalassaemia Transfusion, parenteral iron chelaon
Hb : sickle cell
Some metabolic disorders Neonatal screen & care
Diagnosis & care, live-born aﬀected
Anbiocs, 
basic care
Anbiocs, 
basic care
Improved techniques
Oral iron chelaon
Neonatal screen & care
Antenatal risk idenﬁcaon & prenatal diagnosis
Pre-pregnancy 
genec diagnosisCVS & DNA: 
1st trimester PNDAmnio, IU transfusion
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and support throughout life. Treatment of congenital
malformations often involves surgical repair and in some
cases, as with orofacial clefts, surgery can result in effective
cure. However, many individuals, particularly those who have
undergone complex surgery including cardiac surgery, have a
residual risk of death or disability and require life-long sur-
veillance, with intervention when appropriate. Early diagno-
sis, e.g. through neonatal screening programmes, can improve
outcomes for affected individuals and families. It can enable
early initiation of treatment including rehabilitation where
available thus optimising outcomes, early supportive care for
all individuals and families and can assist families with future
reproductive choices.
The evolution of services over time further complicates the
assessment of trends in mortality and the survival of children
with congenital disorders. Table 5 summarises the evolution
of these interventions by disorder group and decade. The time-
line indicates introduction of the interventions, but this does
not equate to their universal deployment, even in high-income
settings.
Full documentation of survival in the absence of care is
available for many severe disorders, because it requires only
a short period of observation when life expectancy is short, for
example, Trisomy 13 and 18. There are considerable historical
data documenting survival to 20 years at different stages in the
evolution of care, e.g. the data of Czeizel and Sankaranarayan
(1984) (Czeizel and Sankaranarayanan 1984). Observational
data on survival up to 20 or 30 years with current standards of
optimal care are available for many disorders, including con-
genital cardiac disorders (Tennant et al. 2010). Longer-term
survival data are available for some disorders including
Down, Turner and Klinefelter syndromes, oro-facial clefts
and haemoglobin disorders (Baird and Sadovnick 1988;
Bojesen et al. 2004; Christensen et al. 2004; Frid et al. 2004;
Modell et al. 2008; Platt et al. 1994; Price et al. 1986). These
and other available observational data are used to estimate the
survival in the presence and absence of optimal care (further
details are available online (Modell et al. 2017)). One limita-
tion of this approach is that the care received by affected
individuals has evolved over time which may affect the appli-
cation of these data to more recent births.
In MGDb, early mortality, disability and cure are all calculat-
ed using estimated access to diagnostic and treatment services by
the formula described above, and the effectiveness of the inter-
vention on outcomes. The same approach applies for long-term
estimates of years of life lost, lived with disability or cure, num-
bers of living patients and projected effects of policy change.
Conclusion
Congenital disorders are highly diverse in their aetiology and
outcomes. Their diagnosis and management therefore requires
diverse interventions involving numerous different specialist
clinical and genetic services. A large number of interventions,
including improving prepregnancy folate status, anti-D for
rhesus-negative mothers, prenatal diagnosis with the option
of termination of pregnancy where culturally acceptable, or
planned delivery, and early diagnosis and treatment have led
to a substantial reduction in the burden of congenital disorders
in high-income countries over the past 50 years. The largest
burden of these disorders therefore currently lies in low- and
middle-income countries. However, in the absence of strong
diagnostic systems, death and disability due to congenital dis-
orders, even when recorded, may be attributed to other causes,
such as infection.
Interventions have a potential to impact on the overall num-
ber of affected conceptions, and the distribution of outcomes
of these pregnancies, and hence, it is important to consider
access to services when assessing overall burden. In the ab-
sence of robust observational data, estimates generated using
the MGDb methodology can be used to estimate the current
baseline prevalence of conditions, and the potential impact of
scaling-up a particular intervention (Modell et al. 2017). For
example, improved diagnosis and care can extend the survival
of children with incurable disorders, leading to an increasing
number requiring ongoing care year-on-year. Therefore, coun-
tries at all levels of development need to assess their present
situation with respect to congenital disorders, and the short-
and long-term effects of implementing available interventions
on patient numbers and service needs.
Information on current access to packages of care and inter-
ventions form an important part of estimation of the overall
burden of congenital disorders, and the likely potential impact
of investment of resources to scale-up these interventions.
Currently, many countries have limited observational data on
coverage of care. The methods described in this paper can pro-
vide estimates of access to services for countries without data,
thus allowing burden estimation of congenital disorders to be
undertaken for the purposes of policy and programme planning.
However, these estimates rely on numerous assumptions as de-
tailed above. Looking forward, substituting local data on the
coverage of access to different interventions as it becomes avail-
able will substantially strengthen the MGDb burden estimates.
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